Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin

Bibliography

• BACHMAN F: Fibrinolysis. In: Thrombosis and Hemostasis. Verstraete M, Vermylen J, Lijnen R, Arnout J (Eds.), Belgium University Press, Leuven, Belgium (1987):227–266.
   Google Scholar
• HE CS, WILHELM SM, PENTLAND AP et al: Tissue co-operation in a proteolytic cascade activating human interstitial collagenase. Proc. Nati Acad. Sci. USA (1989) 86:2632–2636.
   PubMed Web of Science ®Google Scholar
• MULLEN DE, RORLICH ST: The role of proteinases in cellular invasiveness. Biochim. Biophys. Acta (1983) 695:177–214.
   PubMed Web of Science ®Google Scholar
• TRYGGVASONN K, HOYHTYA M, SALO T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta (1987) 907:191–217.
   PubMed Web of Science ®Google Scholar
• O'GRADY RL, UPFOLD LI, STEPHENS RW: Rat mammary carcinoma cells secrete active collagenase and active latent enzymes in the stroma via plasminogen activator. Int. J. Cancer (1981) 28:509–515.
   PubMed Web of Science ®Google Scholar
• SOBEL GW, MOHLER SR, JONES NW, MILLER KP, PELUSO R: Urokinase: an activator of plasma profibrinolysin extracted from urine. Am.JPhysiol. (1952) 171:768–769.
   Web of Science ®Google Scholar
• WHITE WF, BARLOW GH, MUZEN MM: The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry (1966) 5:2160–2169.
   PubMed Web of Science ®Google Scholar
• BELL WR: The fibrinolytic system in neoplasia. Sem. Thromb. Hemost. (1996) 22:459–478.
   PubMed Web of Science ®Google Scholar
• KIRCHHEIMER JC, WOJTA J, CHRIST G, BINDER BR: Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc. Natl. Acad. Sci. USA (1989) 86:5424–5428.
   PubMed Web of Science ®Google Scholar
• KIRCHHEIMER JC, WOJTA J, CHRIST G, BINDER BR:Proliferation of a human epidermal tumor cell line stimulated by urokinase. Proc. Natl. Acad. Sci. USA (1987) 1:125–128.
   Google Scholar
• ZACHARSKI LR, WOJTUKIEWICZ MZ, COSTANTINI V, ORNSTEIN DL, MEMOLI VA: Pathways of coagula-tion /fibrinolysis activation in malignancy. Semin. Thromb. Hemost. (1992) 1 8 :104–116.
   Web of Science ®Google Scholar
• SAPPINO AP, BUSSO N, BELIN D, VASSALLI JD: Increase of urokinase-type plasminogen activator gene expres-sion in human lung and breast carcinomas. Cancer Res. (1987) 47:4043–4046.
   PubMed Web of Science ®Google Scholar
• TISSOT JD, HAUERT J, BACHMAN F: Characterization of plasminogen activators from normal breast and colon and from breast and colon carcinomas. Int. J Cancer (1984) 34:295–302.
   PubMed Web of Science ®Google Scholar
• PACHECO MM, BRENTANI MM, FRANCO EL, FONTELLES JA, CHARMONE DF, MARQUES LA: Plasminogen activator expression in steroid hormone receptors in female breast cancer: A multifactorial study. Int. J Cancer (1988) 41:798–804.
   PubMed Web of Science ®Google Scholar
• EVERS TL, PATEL J, MADEJA JM: Plasminogen activator activity and composition in human breast cancer. Cancer Res. (1982) 42:219–226.
   PubMed Web of Science ®Google Scholar
• DUFFY MJ, O'GRADY P, DEVANEY D, O'SIORIAN L, FENNELLY JJ, LIJNENE HR: Ur okin ase-plasmin o gen activator, a marker for aggressive breast carcinomas. Cancer (1988) 62:531–533.
   PubMed Web of Science ®Google Scholar
• JANICKE F, SCMITT M, ULM K, GOSSNER W, GRAEFF H: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet (1989) 1:1049.
   Google Scholar
• NEEDHAM GK, NICHOLSON S, ANGUS B, FARNDON JR, HARRIS AL: Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. Cancer Res. (1988) 48:6603–6609.
   PubMed Web of Science ®Google Scholar
• YAMASHITA J, OGAWA M, YAMASHITA S et al: Differen-tial biologic significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br. J. Cancer (1993) 68:524–529.
   PubMed Web of Science ®Google Scholar
• MANGEL WF, TOLEDO DL, NARDULLI AM, REINER GC,NORMAN MJ, KATZENELLENBOGEN BS: Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties. J Steroid Biochem. (1988) 30:79–88.
   PubMedGoogle Scholar
• DUFFY MJ, REILLY D, MCDERMOTT E, O'HIGGINS N, FENNELLY JJ, ANDREASEN PA: Ur okinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer (1994) 74:2276–2280.
   PubMed Web of Science ®Google Scholar
• PRECHTL A, HARBECK N, THOMSSEN C et al: Tumor-biological factors uPA and PAM as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer. Int. J. Biol. Markers (2000) 15:73–78.
   PubMed Web of Science ®Google Scholar
• SIER CF, FELLBAUM C, VERSPAGET HVV et al.: Irnmunolo-calization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopa-thology (1991) 19:231–237.
   PubMed Web of Science ®Google Scholar
• KAWANISHI H, TANAKA K, TAKAI S et al: Irnmunohisto-chemical analysis of plasminogen activator expres-sion in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics. j Surg. Onc. (1991) 46:246–256.
   PubMed Web of Science ®Google Scholar
• WOJUKIEWICZ MZ, ZACHARSKI LR, MEMOLI VA et al: Indirect activation of blood coagulation in colon cancer. Thrombos. Haemostas. (1990) 62:1062–1066.
   Web of Science ®Google Scholar
• KOHGA S, HARVERY SR, WEAVER RM, MARKUS G: Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res. (1985) 45:1787–1796.
   PubMed Web of Science ®Google Scholar
• GANESH S, SIER CF, GRIFFOEN G et al: Prognosticrelevance of plasminogen activators and their inhibi-tors in colorectal cancer. Cancer Res. (1994) 54:4065–4071.
   PubMed Web of Science ®Google Scholar
• MULCAHY HE, DUFFY MJ, GIBBONS D et al.: Urokinase-type plasminogen activator and outcome in Duke's colorectal cancer. Lancet (1994) 344:583–584.
   PubMed Web of Science ®Google Scholar
• SATO T, NISHIMURA G, YONEMURA Y et al.: Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology (1995) 52:347–352.
   PubMed Web of Science ®Google Scholar
• FRELIN C, VIGNE P, LABOUX A, LEZDUNSKI M: The regulation of the intracellular pH in cells from vertebrates. Eur.j Biochem. (1988) 174:3–14.
   PubMedGoogle Scholar
• GRINSTEIN S, ROTIN D, MASON JM: Na+/H+ exchange and growth-factor induced cytosolic p H changes. Role in cellular proliferation. Biochim. Biophys. Acta (1989) 988(1)73–97.
   Google Scholar
• VASSALLI JD, BELIN D: Arniloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. (1987) 214:187–191.
   PubMed Web of Science ®Google Scholar
• KELLEN JA, MIRAKIAN A, KOLIN A: ..--Ar.timetastatic effect of amiloride in an animal tumor model. Anticancer Res. (1988) 8:1373–1376.
   Google Scholar
• WANG Y, JONES CJ, DANG JJ et al.: Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett. (1994) 353:138–142.
   PubMed Web of Science ®Google Scholar
• RAY P, BHATTI R, GADAROWSKI J, BELL N, NASRUDDIN S: Inhibitory effect of amiloride on the urokinase plasminogen activators in prostate cancer. Tumour Biol. (1998) 19:60–64.
   PubMed Web of Science ®Google Scholar
• EVANS DM, SLOAN-STAKLEFF K, ARVAN M, GUYTON DP: Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride. Clin. Exp. Metastasis (1998) 16:353–357.
   PubMed Web of Science ®Google Scholar
• TATSUTA M, IISHI H, BABA M, UEHARA H, NAKAIZUMI A: Chemoprevention by amiloride against experimental carcinogenesis in rat colon induced by azoxymethane. Carcinogenesis (1995) 16:941–942.
   PubMed Web of Science ®Google Scholar
• IISHI H, TATSUTA M, BABA M, YANO H, UEHARA H, NAKAIZUMI A: Suppression by amiloride of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Int. J Cancer (1995) 63:716–719.
   PubMed Web of Science ®Google Scholar
• KOO JY, PAREKH D, TOWNSEND CM et al.: Arniloride inhibits the growth of human colon cancer cells in vitro. Surg. Oncol. (1992) 1:385–389.
   PubMedGoogle Scholar
• PILAT MJ, LEHR JE, QUIGLEY MM, PIENTA KJ: The effect of amiloride on the metastatic properties of prostate cancer in the Dunning rat model. Oncol Rep. (1998) 5:889–892.
   PubMed Web of Science ®Google Scholar
• ALLIEGRO MC, ALLIEGRO MA, CRAGOE EJ, GLASER BM: Arniloride inhibition of angiogenesis in vitro. J. Exp. Zoo]. (1993) 267:245–252.
   PubMedGoogle Scholar
• AVERY RL, CONNOR TB, FARAZDAGHI M: Systemic amiloride inhibits experimentally induced neovascu-larization. Arch. Opththmol. (1990) 108:1474–1476.
   PubMed Web of Science ®Google Scholar
• BENOS DJ: A molecular probe of sodium transport in tissues and cells. Am. J Physiol. (1982) 242:131–145.
   PubMed Web of Science ®Google Scholar
• ULRICH-BAKER MG, WANG P, FITZPATRICK L, JOHNSON LR: Arniloride inhibits rat mucosal ODC activity and DNA synthesis. Am. J Physiol (1988) 254:405–415.
   Google Scholar
• OKAMOTO S, NAKAJIMA T, OKAMOTO U et al: A suppressing effect of epsilon amino-n-caproic acid on the bleeding of dogs, produced with the activation of plasmin in the circulatory blood. Keio J Med. (1959) 8:247–266.
   Google Scholar
• ANDERSSON L, NILSSON IM, NILEHN JE, HEDNER U, GRANSTRAND B, MELANDER B: Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carbox-ylic acid. Scand. j Haematol. (1965) 2:230–247.
   PubMedGoogle Scholar
• MANNUCCI PM: Hemostatic drugs. N Engl. J. Med. (1998)339:245–253.
   PubMed Web of Science ®Google Scholar
• KIKUCHI Y, KIZAWA I, OOMORI K et al: Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. Cancer Res. (1987) 47:592–596.
   PubMed Web of Science ®Google Scholar
• SOMA H, SASHIDA T, YOSHIDA M, MIYASHITA T, NAKAMURA A: Treatment of advanced ovarian cancer with fibrinolytic inhibitor (tranexamic acid). Acta Obstet. Gynecol Scand. (1980) 59:285–287.
   PubMed Web of Science ®Google Scholar
• KIKUCHI Y, KIZAWA I, OOMORI K, MATSUDA M, KATO K: Adjuvant effects of tranexamic acid to chemotherapy in ovarian cancer patients with large amounts of ascites. Acta Obstet. Gynecol Scand. (1986) 65:453–456.
   PubMed Web of Science ®Google Scholar
• SERDENGECTI S, BUYUKUNAL E, MOLINAS N et al: Overall survival results of non-small cell lung cancer patients: chemotherapy alone versus chemotherapy with combined immunomodulation. Chemiotherapia (1988) 7:122–126.
   PubMedGoogle Scholar
• FRITZ H, WUNDERER G: Biochemistry and applicationof aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung (1983) 33:479–494.
   PubMed Web of Science ®Google Scholar
• HOFFMANN H, SIEBECK M, THETTER O, JOCHUM M, FRITZ H: Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo. In: Kinins V. Part B. Advances in Experi-mental Medicine and Biology. Abe K, Moriya H, Fujii S (Eds.), Plenum Press, NY, USA (1989) 247B:35–42.
   Google Scholar
• LAHTEENMAKI K, VIRKOLA R, POULTER R, RUUSELA P, KUKKONEN M, KORHONEN TK: Bacterial plasminogen receptors: in vitroevidence for a role in degradation of the mammalian extracellular matrix. Inf. Immun. (1995) 63:3659–3664.
   PubMed Web of Science ®Google Scholar
• LEMMER HJ, STANFORD W, BONNEY SL et al.: Aprotinin for coronary bypass operations: Efficacy, safety and influence on early saphenous vein graft patency. Thor. Cardiovasc. Surg. (1994) 107:543–553.
   Web of Science ®Google Scholar
• NEUHAUS P, BECHSTEIN WO, LEFEBRE B, BLUMHARDT G, SLAMA K: Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet (1989) 2:924–925.
   PubMed Web of Science ®Google Scholar
• DAVIS R, WHITTINGTON R: Aprotinin: A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs (1995) 49:954–983.
   PubMed Web of Science ®Google Scholar
• DIETRICH W, SPATH P, EBELL A, RICHTER JA: Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J. Thorac. Cardiovasc. Surg. (1997) 113:194–201.
   PubMed Web of Science ®Google Scholar
• HAVEL M, GRABENWOGER F, SCHNEIDER J et al.: Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac. Cardiovasc. Surg. (1994) 107:807–810.
   PubMed Web of Science ®Google Scholar
• KALANGOS A, TAYYARECI G, PRETRE R, DI DIO P, SEZERMAN O: Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur. J. Cardiothorac. Surg. (1994) 8:651–656.
   PubMed Web of Science ®Google Scholar
• LASS M, WELZ A, KOCHS M, MAYER G, SCHVVANDT M, HANNEKUM A: Aprotinin in elective primary bypass surgery: graft patency and clinical efficacy. Eur. Cardiothorac. Surg. (1995) 9:206–210.
   PubMed Web of Science ®Google Scholar
• LATNER A, LONGSTAFF E, TURNER GA: Antitumor activity of aprotinin. Br. J. Cancer (1974) 30:60–67.
   PubMed Web of Science ®Google Scholar
• OHKOSHI M: Effect of aprotinin on growth of 3-methylchloranthrene-induced squamous cell carcinoma in mice. Gann. (1980) 71:246–250.
   PubMedGoogle Scholar
• LAGE A, DIAZ J, GONZALEZ I: Effect of proteinase inhibitor in experimental tumors. Neoplasma (1978) 25:257–259.
   PubMed Web of Science ®Google Scholar
• ZBYTNIEWSKI Z, DREWA G, KANCLERZ A: The effect of trasylol and p-aminomethylbenzoic acid on the experimental metastasis of transplantable melanotic melanoma in golden hamsters. Archly. Fur. Geschwulst. (1977) 47:400–404.
   PubMedGoogle Scholar
• GIRALDI T, NISI C, SAVA G: Lysosomal enzyme inhibi-tors and antimetastatic activity in the mouse. Eur. Cancer (1977) 13:1321–1323.
   PubMed Web of Science ®Google Scholar
• MONDEN T, MORIMOTO H, SHIMANO T et al: Use offibrinogen to enhance the antitumor effect of OK-432. Cancer (1992) 69:636–642.
   PubMed Web of Science ®Google Scholar
• LENTSCHENER C, LI H, FRANCO D et al.:Intraoperatively-administered aprotinin and survival after elective liver resection for colorectal cancer metastasis. A preliminary study. Fibrinolysis Proteolysis (1999) 13:39–45.
   Web of Science ®Google Scholar
• RABBANI SA, HARAKIDAS P, DAVIDSON DJ, HENKIN J,MAZAR AP: Prevention of prostate - cancer metastasis in vivoby a novel synthetic inhibitor of urokinase-type plasminogen activator. Int. J. Cancer (1995) 63:840–845.
   PubMed Web of Science ®Google Scholar
• EVANS DM, SLOAN-STAKLEFF KD: Maximum effect of urokinase plasminogen activator in the control of invasion and metastasis of rat mammary cancer. Invasion Metastasis (1999) 18:252–260.
   Google Scholar